Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Glucagon Infusion Clear all
Completed Phase 2 Interventional Results available

PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients

NCT02081001
View directory record Official record
Conditions
Hypoglycemia
Interventions
Novo Nordisk GlucaGen®, G-Pump™ (glucagon infusion)
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 20, 2026, 11:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Closed-loop Glucose Control for Automated Management of Type 1 Diabetes

NCT00811317
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed-loop
Device
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 20, 2026, 11:07 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery

NCT07212868
View directory record Official record
Conditions
Non-Diabetic
Interventions
REMD-477 versus Placebo, Exogenous glucagon versus saline infusion
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 11:07 AM EDT
Terminated Phase 2 Interventional Results available

The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

NCT00798590
View directory record Official record
Conditions
Critically Ill, Hypoglycemia
Interventions
Glucagon-Like Peptide-1, Saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 11:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia

NCT03255629
View directory record Official record
Conditions
Post-bariatric Hypoglycemia
Interventions
glucagon, Closed loop glucagon pump
Drug · Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Oct 20, 2026, 11:07 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion

NCT05264727
View directory record Official record
Conditions
Healthy, Type 2 Diabetes, Obesity
Interventions
Dextrose, Clinisol 15%
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 20, 2026, 11:07 AM EDT
Terminated Not applicable Interventional

Glucagon Counterregulation in Type 1 Diabetes

NCT03547427
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Basal insulin alone, Basal pramlintide and reduced basal insulin, CGM, Acetaminophen test, Insulin-induced hypoglycemia, Exercise-induced hypoglycemia
Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 20, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

NCT06445075
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Apitegromab, Placebo, Tirzepatide
Drug
Lead sponsor
Scholar Rock, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
7
States / cities
Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 20, 2026, 11:07 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism

NCT04300049
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Glucagon Infusion, Saline
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 20, 2026, 11:07 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy

NCT01951716
View directory record Official record
Conditions
Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions
Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 20, 2026, 11:07 AM EDT
Withdrawn Early Phase 1 Interventional

Glucagon-like Peptide-1 in Type 1 Diabetes

NCT04355832
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Glucagon-like peptide-1, Placebos
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 20, 2026, 11:07 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Studies of Insulin and Glucagon Action in the Liver

NCT07300982
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Glucagon, Saline (placebo)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 20, 2026, 11:07 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Splanchnic Venous Capacitance in Postural Tachycardia Syndrome

NCT05375968
View directory record Official record
Conditions
Postural Tachycardia Syndrome (POTS)
Interventions
Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients, Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls, Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2, Compare change is SVC and SMA flow due to saline
Diagnostic Test · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 20, 2026, 11:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes

NCT01021865
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus Type 2
Interventions
Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 20, 2026, 11:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

NCT04459338
View directory record Official record
Conditions
Healthy
Interventions
Exendin-9,39, Saline
Biological · Other
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 20, 2026, 11:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity

NCT00897676
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin-(9-39), placebo
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 20, 2026, 11:07 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

NCT01803451
View directory record Official record
Conditions
Post-bariatric Surgery
Interventions
exendin -(9-39)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 20, 2026, 11:07 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

NCT00835328
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin (9-39), Vehicle
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
Up to 12 Months
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 20, 2026, 11:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

GLP1R Polymorphisms and Response to GLP1

NCT00588380
View directory record Official record
Conditions
Diabetes
Interventions
GLP-1
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 40 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Oct 20, 2026, 11:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glucagon Regulation of Glucose Metabolism

NCT04347252
View directory record Official record
Conditions
Insulin Secretion
Interventions
Glucagon
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 20, 2026, 11:07 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Insulin and Insulin Pulses During Fasting

NCT06424015
View directory record Official record
Conditions
PreDiabetes
Interventions
Intralipid and heparin, Saline
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 20, 2026, 11:07 AM EDT
Terminated Phase 2 Interventional Results available

Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery

NCT00966654
View directory record Official record
Conditions
CABG
Interventions
Placebo, GLP-1 (7-36) amide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 20, 2026, 11:07 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Liver Glycogen and Hypoglycemia in Humans

NCT03241706
View directory record Official record
Conditions
Hypoglycemia; Iatrogenic
Interventions
Low Fructose, Saline, Somatostatin, Insulin, Glucagon, Dextrose solution, High Fructose
Drug
Lead sponsor
Jason Winnick
Other
Eligibility
21 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 20, 2026, 11:07 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes

NCT02398383
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Interventions
Oral Glucose Tolerance Test, Mixed Meal Tolerance Test, Hypoglycemic Clamp
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 20, 2026, 11:07 AM EDT